DR. DOUGLAS DANIEL RICHMAN, MD
Osteopathic Medicine in San Diego, CA
License number
California G21088
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
2
Va San Diego Healthcare System, San Diego, CA 92161
9551 La Jolla Farms Rd, La Jolla, CA 92037
9551 La Jolla Farms Rd, La Jolla, CA 92037
Phone
(858) 552-7439
(858) 552-7445 (Fax)
(858) 552-7445 (Fax)
Personal information
See more information about DOUGLAS DANIEL RICHMAN at radaris.comName
Address
Phone
9551 La Jolla Farms Rd, La Jolla, CA 92037
9551 La Jolla Farms Rd, La Jolla, CA 92037
Professional information
Dr. Douglas D Richman, San Diego CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
VA Medical Center Infect Dis
3350 La Jolla Village Dr SUITE MC111F, San Diego 92161
(858) 552-7446 (Phone)
3350 La Jolla Village Dr SUITE MC111F, San Diego 92161
(858) 552-7446 (Phone)
Certifications:
Infectious Disease, 1976, Internal Medicine, 1973
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Stanford University
Graduated: 1970
Stanford Hosps
Stanford University
Graduated: 1970
Stanford Hosps
Douglas Daniel Richman, La Jolla CA
Specialties:
Infectious Disease Specialist
Address:
9500 Gilman Dr, La Jolla, CA 92093
Va San Diego Healthcare System, San Diego, CA 92161
Va San Diego Healthcare System, San Diego, CA 92161
Education:
Stanford University, School of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)*
Douglas Daniel Richman, San Diego CA
Specialties:
Internal Medicine, Infectious Disease, Pathology
Work:
Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161
3350 La Jolla Village Dr, San Diego, CA 92161
Education:
Stanford University (1970)
Antiviral Compounds And Methods Of Administration
US Patent:
6686462, Feb 3, 2004
Filed:
Feb 28, 1997
Appl. No.:
08/808847
Inventors:
Andre Rosowsky - Needham MA
Karl Y. Hostetler - Del Mar CA
James R. Beadle - San Diego CA
Ganesh D. Kini - San Diego CA
Douglas D. Richman - La Jolla CA
Karl Y. Hostetler - Del Mar CA
James R. Beadle - San Diego CA
Ganesh D. Kini - San Diego CA
Douglas D. Richman - La Jolla CA
Assignee:
The Regents of the University of California - Oakland CA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 3170
US Classification:
536 268
Abstract:
The invention provides lipophilic phosphonoacid/nucleoside conjugates that exhibit exceptional antiviral activity, including activity against drug-resistant HIV strains. Compounds of the invention include phosphonoacid/nucleoside conjugates where the carboxyl group and phosphonyl groups of the phosphonacid are esterified whereby the compound contains at least one lipophilic group and at least one nucleoside group.
Methods For Determining The Presence Of Antibodies Blocking Viral Infection
US Patent:
2011003, Feb 10, 2011
Filed:
Dec 10, 2009
Appl. No.:
12/635539
Inventors:
DOUGLAS RICHMAN - LA JOLLA CA, US
MARY T. WRIN - FREMONT CA, US
SUSAN LITTLE - SAN DIEGO CA, US
CHRISTOS J. PETROPOULOS - HALF MOON BAY CA, US
NEIL T. PARKIN - BELMONT CA, US
JEANNETTE WHITCOMB - SAN MATEO CA, US
WEI HUANG - FOSTER CITY CA, US
MARY T. WRIN - FREMONT CA, US
SUSAN LITTLE - SAN DIEGO CA, US
CHRISTOS J. PETROPOULOS - HALF MOON BAY CA, US
NEIL T. PARKIN - BELMONT CA, US
JEANNETTE WHITCOMB - SAN MATEO CA, US
WEI HUANG - FOSTER CITY CA, US
Assignee:
MONOGRAM BIOSCIENCES, INC. - SOUTH SAN FRANCISCO CA
International Classification:
C12Q 1/70
US Classification:
435 5
Abstract:
The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
Compositions And Methods For Evaluating Viral Receptor/Co-Receptor Usage And Inhibitors Of Virus Entry Using Recombinant Virus Assays
US Patent:
2005021, Sep 29, 2005
Filed:
Feb 14, 2003
Appl. No.:
10/504921
Inventors:
Douglas Richman - La Jolla CA, US
Mary Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US
Jeannette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Mary Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US
Jeannette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
International Classification:
C12Q001/70, C12N015/86
US Classification:
435005000, 435456000
Abstract:
The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
Method Of Evaluating A Patient Antibody Response To Envelope Proteins Of A Virus
US Patent:
7247439, Jul 24, 2007
Filed:
Feb 15, 2002
Appl. No.:
10/077027
Inventors:
Douglas Richman - La Jolla CA, US
Mary T. Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeannette M. Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Mary T. Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeannette M. Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Assignee:
Monogram Biosciences, Inc. - South San Francisco CA
International Classification:
G01N 33/53
US Classification:
435 71, 435 5, 435 6, 435 721, 435 691, 4353201, 514 44, 536 2372
Abstract:
The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
Methods For Increasing A Cytotoxic T Lymphocyte Response In Vivo
US Patent:
2003014, Aug 7, 2003
Filed:
Jan 10, 2003
Appl. No.:
10/339885
Inventors:
Eyal Raz - Del Mar CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - Leucadia CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - Leucadia CA, US
International Classification:
A61K048/00
US Classification:
424/093210, 514/044000
Abstract:
The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
Methods For Increasing A Cytotoxic T Lymphocyte Response In Vivo
US Patent:
2003014, Jul 31, 2003
Filed:
Jan 10, 2003
Appl. No.:
10/340275
Inventors:
Eyal Raz - Del Mar CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - Leucadia CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - Leucadia CA, US
International Classification:
A61K048/00
US Classification:
424/093210, 514/044000
Abstract:
The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
Methods For Increasing A Cytotoxic T Lymphocyte Response In Vivo
US Patent:
2002014, Oct 3, 2002
Filed:
Mar 28, 2001
Appl. No.:
09/820484
Inventors:
Eyal Raz - Del Mar CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - San Diego CA, US
Hearn Cho - New York NY, US
Douglas Richman - La Jolla CA, US
Anthony Horner - San Diego CA, US
International Classification:
A61K048/00
US Classification:
514/044000
Abstract:
The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.